Cracking The Code: Understanding Analyst Reviews For ADMA Biologics

In the latest quarter, 4 analysts provided ratings for ADMA Biologics ADMA, showcasing a mix of bullish and bearish perspectives.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated ADMA Biologics and provided 12-month price targets. The average target is $6.5, accompanied by a high estimate of $9.00 and a low estimate of $5.00. This current average has increased by 8.33% from the previous average price target of $6.00.

Breaking Down Analyst Ratings: A Detailed Examination

The standing of ADMA Biologics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ADMA Biologics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ADMA Biologics compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of ADMA Biologics's stock. This analysis reveals shifts in analysts' expectations over time.

For valuable insights into ADMA Biologics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on ADMA Biologics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering ADMA Biologics: A Closer Look

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.

Understanding the Numbers: ADMA Biologics's Finances

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Positive Revenue Trend: Examining ADMA Biologics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 63.72% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: ADMA Biologics's net margin is impressive, surpassing industry averages. With a net margin of 3.81%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): ADMA Biologics's ROE excels beyond industry benchmarks, reaching 1.72%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): ADMA Biologics's ROA excels beyond industry benchmarks, reaching 0.74%. This signifies efficient management of assets and strong financial health.

Debt Management: ADMA Biologics's debt-to-equity ratio surpasses industry norms, standing at 1.01. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Significance of Analyst Ratings Explained

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.